Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Innovative Oncology Nurses Break Down Communication Barriers for Patients Who Are Deaf or Hard of Hearing
    Special Populations
    Innovative Oncology Nurses Break Down Communication Barriers for Patients Who Are Deaf or Hard of Hearing
    March 10, 2023
    How I Practice Mindfulness as an Oncology Nurse
    Nurse well-being
    How I Practice Mindfulness as an Oncology Nurse
    March 03, 2023
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    Oncology nurse education
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    January 13, 2023
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    Pancreatic cancer
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    November 11, 2022
    The Life of Marie Curie and Her Contributions to Oncology
    Cancer treatments
    The Life of Marie Curie and Her Contributions to Oncology
    November 07, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Chemotherapy

    Platinum Chemo Improves TNBC Survival for Patients Younger Than 50
    Chemotherapy

    Platinum Chemo Improves TNBC Survival for Patients Younger Than 50

    Adding carboplatin to standard neoadjuvant chemotherapy for patients with triple-negative breast cancer improves complete response, event-free survival, and overall survival, researchers reported in study findings presented in abstract GS5-01 during the 2022 San Antonio Breast Cancer Symposium. 

    March 29, 2023
    During or After Chemo, Exercise Fights Fatigue and Supports Cancer Recovery
    Chemotherapy

    During or After Chemo, Exercise Fights Fatigue and Supports Cancer Recovery

    Patients who engage in physical activity during or after cancer treatment are less fatigued and return to their usual daily activities faster than those who don’t exercise, researchers reported in JACC: CardioOncology. The benefit is highest among patients who are active during treatment but still pronounced for those who resume physical activity after completing treatment.

    January 04, 2023
    Chemo Combo May Be a Bladder Cancer Treatment Alternative During BCG Shortage
    Chemotherapy

    Chemo Combo May Be a Bladder Cancer Treatment Alternative During BCG Shortage

    Overall survival among patients with non–muscle-invasive bladder cancer who are treated with adjuvant gemcitabine and docetaxel is comparable to overall survival for treatment with bacillus Calmette-Guérin (BCG), researchers reported in the Journal of Urology. The evidence could support a treatment alternative for high-risk patients during the BCG shortage.

    December 21, 2022
    Biomarkers Are Associated With Frailty After Chemo for Breast Cancer
    Breast cancer

    Biomarkers Are Associated With Frailty After Chemo for Breast Cancer

    High levels of interleukin-6 (IL-6) and C-reactive protein before chemotherapy for breast cancer may predict a patient’s propensity to develop clinical decline and frailty after treatment, according to study findings that researchers reported in the Journal of Clinical Oncology.

    November 09, 2022
    Cortisol Biomarkers Help Researchers Understand Chemotherapy-Induced Peripheral Neuropathy
    Chemotherapy

    Cortisol Biomarkers Help Researchers Understand Chemotherapy-Induced Peripheral Neuropathy

    Clinicians and researchers know little about the mechanisms for chemotherapy-induced peripheral neuropathy, a side effect of neurotoxic agents that can cause numbness, tingling, and pain in the upper and lower extremities. Until recently, mechanism-based treatment was difficult, but biomarkers are helping nurse scientists identify a potential connection to the hypothalamic-pituitary-adrenal axis.

    November 03, 2022
    Nurses Have Immediate Access to Necessary Medications and Supplies With Hypersensitivity Reaction Kits
    Oncologic emergencies

    Nurses Have Immediate Access to Necessary Medications and Supplies With Hypersensitivity Reaction Kits

    Biologic agents or chemotherapies can trigger hypersensitivity reactions, which occur when a patient’s immune system identifies an agent as an antigen and initiates a complex reaction involving sensitization of T lymphocytes and macrophages, production of antibodies, and release of histamine. Developing and implementing a hypersensitivity kit containing all necessary medications and associated protocols allows nurses to immediately implement management when reactions occur.

    October 13, 2022
    Strategies to Promote Safe Medication Administration Practices
    Chemotherapy

    Strategies to Promote Safe Medication Administration Practices

    Medication administration is a high-risk process that requires critical thinking, efficient decision-making, attention to detail, and a foundational knowledge of basic pharmacology. The process is not a single task but a cascade of events that include handling, ordering, preparing, dispensing, administering, and monitoring. Although nurses’ involvement varies at each phase, the risk for errors always exists, and consequences can have a lifelong impact on patients, families, and healthcare workers. Nurses can use the following strategies in their responsibility as the last line of defense for safe medication administration.

    October 06, 2022
    ONS Bridge

    Follow the Evidence When Using Scalp Cooling for Cancer Alopecia

    Scalp cooling, also known as cryotherapy, may reduce the risk of chemotherapy-induced alopecia (CIA) in patients with cancer, but how do you know if the therapy is right for your patients? According to speakers at an ONS BridgeTM virtual conference session on September 9, 2021, start with the evidence.

    September 09, 2021
    The Evidence Is Building for ACE Inhibitors in Anthracycline-Associated Cardiotoxicity
    Research

    The Evidence Is Building for ACE Inhibitors in Anthracycline-Associated Cardiotoxicity

    Cardiac toxicities are associated with many types of cancer therapies, with both length of and time since treatment increasing a patient’s risk for the adverse event. Anthracycline chemotherapies are among the oldest agents still used for a variety of cancer diagnoses, and as cancer survivorship continues to grow, more patients are presenting with late-onset cardiac complications.

    July 13, 2021
    The Case of the CIA-Combatting Combination
    Clinical practice

    The Case of the CIA-Combatting Combination

    Sofia is a 35-year-old patient who identifies as female who was recently diagnosed with breast cancer and is concerned with experiencing chemotherapy-induced alopecia (CIA) as an adverse event from treatment. She comes in for her first infusion of adriamycin plus cyclophosphamide and is using scalp cooling to prevent hair loss. She works as a project manager, which requires her to keep her camera on for her many daily video calls. She is very anxious about losing her hair and asks you if taking minoxidil in addition to the scalp cooling treatment would guarantee she maintains her hair. 

    June 25, 2021
    ONS Congress

    Cognitive Impairment Is Much More Than “Chemo Brain”

    Cancer-related cognitive impairment (CRCI) is a result of a slew of confounding variables, including cancer, its treatments, and other factors. Although the side effect is expected, it doesn’t have to be accepted. Patients have many options to manage CRCI, and nurses have an important role in education, assessment, and referral to support, according to speakers at a session on April 29, 2021, during the 46th Annual ONS Congress™. 

    April 29, 2021
    FDA Approves Trilaciclib to Reduce Chemotherapy-Induced Myelosuppression
    Chemotherapy

    FDA Approves Trilaciclib to Reduce Chemotherapy-Induced Myelosuppression

    On February 12, 2021, the U.S. Food and Drug Administration (FDA) approved trilaciclib (Cosela™) as the first therapy in its class to reduce the frequency of chemotherapy-induced myelosuppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer. Trilaciclib inhibits cyclin-dependent kinase 4/6 (CDK 4/6) enzymes to prevent bone marrow damage.   

    February 15, 2021
    Adding Nivolumab to Chemo Improves Survival for Advanced Gastric Cancer
    Chemotherapy

    Adding Nivolumab to Chemo Improves Survival for Advanced Gastric Cancer

    First-line therapy combining nivolumab with chemotherapy improved median overall survival rates in patients with PD-L1-expressing gastric cancer by 3.3 months in a large international, multicenter trial. The findings were reported during the 2020 European Society for Medical Oncology virtual meeting.

    December 30, 2020
    The Case of the Terrible Taste
    Chemotherapy

    The Case of the Terrible Taste

    Tanya is a 46-year-old woman with leukemia. She recently finished induction therapy, and her oncologist told her she is ready to receive a hematopoietic stem cell transplant. You speak with Tanya about what to expect in the upcoming weeks before her transplant, but she interrupts you: “Nothing tastes good anymore. I am so scared because I thought I completed chemotherapy. The doctor just told me I have to get more before my transplant. Every time I get chemotherapy, I lose my appetite.”

    November 06, 2020
    Manage Immune-Related Adverse Events in Patients on Durvalumab
    Adverse events

    Manage Immune-Related Adverse Events in Patients on Durvalumab

    Durvalumab immunotherapy became a new standard of care for patients with stage III unresectable non-small cell lung cancer whose disease did not progress following two cycles of platinum-based chemoradiotherapy after its approval in February 2018, and in March 2020, its indication was expanded for use as first-line treatment in patients with extensive-stage small cell lung cancer as well. Key to keeping patients on immunotherapy treatment and giving them the best chance at long-term survival is effective management of immune-related adverse events.

    August 11, 2020
    Polypharmacy Before Cancer Is Predictive of Post-Treatment Hospitalization
    Chemotherapy

    Polypharmacy Before Cancer Is Predictive of Post-Treatment Hospitalization

    Patients who take five or more medications in the six months before beginning IV chemotherapy for a cancer diagnosis are more likely to be hospitalized after their chemotherapy treatment, according to the findings from a new study published in the Journal of Geriatric Oncology.

    June 19, 2020
    Dietary Supplements May Affect Breast Cancer Chemo Outcomes
    Chemotherapy

    Dietary Supplements May Affect Breast Cancer Chemo Outcomes

    Antioxidant supplements are associated with increased disease recurrence and statistically nonsignificant increased risk of mortality in patients with breast cancer who were receiving cyclophosphamide, doxorubicin, and paclitaxel, according to findings from a study reported in the Journal of Clinical Oncology.

    May 13, 2020
    Educational Framework Offers Guidance for Oral Chemo Safety at Home
    Safety

    Educational Framework Offers Guidance for Oral Chemo Safety at Home

    One aspect that ambulatory oncology nurses must consider in the greater staffing conversation is the time spent on educating patients and caregivers about oral chemotherapy safety in the home setting. Developing an educational framework to guide those conversations not only ensures that all critical information is covered but also that it’s delivered in a standard and efficient process. 

    March 10, 2020
    The Case of the Candy-Coated (Mis)Conception
    Cancer research

    The Case of the Candy-Coated (Mis)Conception

    P.G. is a 54-year-old woman who presents to the infusion center to receive her second cycle of chemotherapy for breast cancer. As her oncology nurse, you check the chemotherapy orders and patient history and are concerned to see that her weight has dropped by 10% from baseline, necessitating a change in dosing.

    February 28, 2020
    Which of the Following Should Not Be Recommended to Patients Taking Oral Antineoplastic Medication at Home?
    Patient Education

    Which of the Following Should Not Be Recommended to Patients Taking Oral Antineoplastic Medication at Home?

    Which of the Following Should Not Be Recommended to Patients Taking Oral Antineoplastic Medication at Home?

    A. Handwashing before and after handling the medication is important.

    B. Use a urinal or bedpan instead of a toilet to reduce the risk of contamination via body fluids.

    C. Keep oral antineoplastic drugs separate from other medications.

    D. Do not touch tablets or capsules with bare hands; wear disposable gloves.      

    March 15, 2019
    Adding Chemo to Immunotherapy May Resensitize Resistant Tumors
    Immunotherapy

    Adding Chemo to Immunotherapy May Resensitize Resistant Tumors

    Using chemotherapy with immune checkpoint inhibitors may reactivate tumors’ responses to immunotherapy, researchers concluded in a review article published in the Annals of Oncology.

    March 13, 2019
    San Antonio Breast Cancer Symposium

    Highly Emetogenic Chemotherapy Still Contributes to Potentially Avoidable Adverse Events

    The Centers for Medicare and Medicaid Services (CMS) implemented an oncology outcome measure to assess the quality of care and determine outpatient hospital payment (OP-35: Admissions and Emergency Department Visits for Patients Receiving Outpatient Chemotherapy). The measure assesses 30-day postchemotherapy rates of inpatient or emergency department (ED) events deemed “potentially avoidable” because of an association with any of the 10 CMS-defined toxicities: anemia, dehydration, diarrhea, fever, nausea, emesis, neutropenia, pain, pneumonia, or sepsis. Researchers sought to assess those events when linked to highly emetogenic chemotherapy (HEC) in patients treated with anthracycline plus cyclophosphamide (AC), carboplatin, or cisplatin. They presented the findings at the San Antonio Breast Cancer Symposium on December 7, 2018.

    December 07, 2018
    U.S. Spending on Antineoplastics Nearly Doubles From 2011–2016
    Treatments

    U.S. Spending on Antineoplastics Nearly Doubles From 2011–2016

    Dollars spent on cancer drugs increased from $26.8 billion in 2011 to $42.1 billion in 2016, according to the results of a study reported in the Journal of Oncology Practice.

    December 05, 2018
    Chemotherapy Is Still a Staple in Treatment Plans. Here’s a Fresh Look at a Familiar Treatment Option
    Treatments

    Chemotherapy Is Still a Staple in Treatment Plans. Here’s a Fresh Look at a Familiar Treatment Option

    Despite all of the new drugs approved in recent years—particularly immunotherapies, oral agents, and biosimilars—that have forced nurses to consider many novel approaches to patient care, the importance of chemotherapy in cancer treatment has remained a constant. In a field where it feels like no two days are the same and new drugs emerge on a rolling basis, chemotherapy continues to be a staple in cancer treatment plans and safety and administration principles remain constant. 

    November 26, 2018
    ONS Tackles Oral Chemotherapy Complexities
    Oral adherence

    ONS Tackles Oral Chemotherapy Complexities

    To ensure that patients and providers are equipped with the latest, most up-to-date knowledge and resources, ONS routinely works with patient advocacy groups, subject matter experts, and other provider organizations to develop and refine critical information for clinical practice. Following safety standards and meeting patient education requirements are critical to successful oral chemotherapy practice.

    November 06, 2018
    Which RN is Competent in Chemotherapy Administration?
    Chemotherapy

    Which RN Is Competent in Chemotherapy Administration?

    Which RN is Competent in Chemotherapy Administration?

    1. One that took a chemotherapy course online 2 years ago and recently completed their annual education.
    2. One that witnessed a chemotherapy competent nurse administer chemotherapy orally and parenterally on five separate occasions
    3. One that took a chemotherapy course offered by her hospital and completed an administration checklist with a chemo competent nurse          
    4. One who works on a unit that cares for patients receiving chemotherapy
    November 01, 2018
    How Oncology Nurses Support Non-Oncology Units Administering Chemotherapy
    Safety

    How Oncology Nurses Support Non-Oncology Units Administering Chemotherapy

    Most patients and practitioners associate chemotherapy with cancer treatments, yet the drugs are also used to treat a number of autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, antineutrophil cytoplasmic antibody–associated vasculitis, and systemic lupus erythematosus. 

    October 23, 2018
    FDA Approves Epoetin Alfa-Epbx as a Biosimilar to Epoetin Alfa
    U.S. Food and Drug Administration (FDA)

    FDA Approves Epoetin Alfa-Epbx as a Biosimilar to Epoetin Alfa

    On May 15, 2018, the U.S. Food and Drug Administration approved epoetin alfa-epbx (Retacrit™) as a biosimilar to epoetin alfa (Epogen/Procrit) for the treatment of anemia due to chronic kidney disease.

    May 16, 2018
    What’s the Preferred Method for Vincristine Administration When Treating a Patient With Lymphoma or Leukemia?
    Chemotherapy

    What’s the Preferred Method for Vincristine Administration When Treating a Patient With Lymphoma or Leukemia?

    What is the preferred method to administer vincristine into a peripheral IV site when treating a patient with lymphoma or leukemia? 

    A. Direct IV push by syringe 

    B. By syringe through free-flowing IV fluids (side-arm technique) 

    C. Gravity drip using an IV minibag 

    D. By minibag using an IV pump 

    May 10, 2018
    Evidence for Nephrotoxicity Prevention With Cisplatin Therapy Is Still Limited
    Treatment side effects

    Evidence for Nephrotoxicity Prevention With Cisplatin Therapy Is Still Limited

    Cisplatin chemotherapy is used alone or in combination to treat a variety of cancers, including ovarian, testicular, lung, cervical, bladder, head and neck, and gastric cancers as well as lymphoma, melanoma, and more. Although it offers options for many cancer types, its use may result in nephrotoxicity, a dose-limiting side effect. Use of hydration and diuretics may help reduce its incidence, but no standards or best practices are in place to guide those treatments.

    May 08, 2018
    Which Gene Plays a Role in Tumor Resistance?
    Chemotherapy

    Which Gene Plays a Role in Tumor Resistance?

    Which of the following is gene that may play a role in tumor resistance to chemotherapy?

    A. NRAS

    B. APC

    C. p53

    D. VHL

    April 26, 2018
    Which Is Not an ASCO/ONS Chemotherapy Safety Standard?
    Chemotherapy

    Which Is Not an ASCO/ONS Chemotherapy Safety Standard?

    Which of the following is NOT an ASCO/ONS Chemotherapy Administration Safety Standard?

    A. Chemotherapy orders include sequencing of agents, when applicable.  

    B. A licensed independent practitioner is on-site and readily available to staff where chemotherapy is administered.

    C. Two chemotherapy-competent RNs must be in the infusion area at all times when chemotherapy is infusing.  

    D. If chemotherapy is administered in a non-healthcare setting, a second identifier such as a driver’s license, is used to verify the patient’s identity.  

    April 19, 2018
    ONS Shares Chemotherapy Education in Sub-Saharan Africa
    Nursing education

    ONS Shares Chemotherapy Education in Sub-Saharan Africa

    For sub-Saharan African (SSA) countries, cancer incidence is on the rise. The increase in cancer rates can be attributed to several factors, including economic and social development and infectious disease rates. In that part of the world, many healthcare professionals don’t have access to up-to-date information regarding safe chemotherapy handling and administration. The American Cancer Society (ACS) and Clinton Health Access Initiative (CHAI) developed the ChemoSafe program to share critical information and resource acquisition focused on safe chemotherapy administration and cancer treatments with healthcare providers in SSA. ONS provided specific nursing content to support the ChemoSafe initiative, including educational materials and courses.

    April 05, 2018
    Nursing Interventions Help Reduce Chemotherapy Symptom Burden
    Symptom management

    Motivational Interviewing Nursing Interventions Help Reduce Chemotherapy Symptom Burden

    Nursing interventions such as coaching, telephone follow-up, and home care have been reported with inconsistent results. In their article in the January 2018 issue of the Oncology Nursing Forum, Coolbrandt et al. discussed the evaluation of a nursing intervention focused on patient education and self-management to reduce symptom distress in outpatients with cancer.

    February 12, 2018
    Safety information on Varubi (Rolapitant) Injectable Emulsion
    U.S. Food and Drug Administration (FDA)

    Safety Information on Varubi (Rolapitant) Injectable Emulsion

    The Oncology Center of Excellence of the U.S. Food and Drug Administration (FDA) is informing healthcare providers about new safety information for Varubi® (rolapitant) injectable emulsion, a substance P/neurokinin (NK-1) receptor antagonist indicated for the prevention of delayed nausea and vomiting associated with cancer chemotherapy in adults.

    January 17, 2018
    How Are You Tracking Patients on Oral Chemotherapy?
    Chemotherapy

    How Are You Tracking Patients on Oral Chemotherapy?

    Oral cancer treatments are effective and practical and can provide a level of flexibility for patients, allowing them to seamlessly continue their treatments without the burden of infusion visits. With many patients receiving oral chemotherapy, oncology nurses must recognize complications that can arise regarding procedure and documentation in practice.  

    December 29, 2017
    peripheral neuropathy from chemo
    Research

    Discovery of Peripheral Neuropathy Cause May Lead to Preventive Treatments

    Researchers have found that taxane chemotherapies such as paclitaxel impede a protein called Bclw, which leads to the side effect of peripheral neuropathy. The study results were published in Neuron.

    December 20, 2017
    San Antonio Breast Cancer Symposium

    PRAEGNANT Breast Cancer Registry Suggests Chemotherapy Offers Little Benefit

    A group of German researchers attempting to identify predictors for a decision against an antihormonal treatment (AHT) were unable to show that patients benefited from chemotherapy. They presented their results on Thursday, December 7, during a poster session at the San Antonio Breast Cancer Symposium.

    December 07, 2017
    What’s the Procedure for Delivering Chemotherapy to an Inpatient Unit?
    Safety

    What’s the Procedure for Delivering Chemotherapy to an Inpatient Unit?

    The elements of an oncology unit are often very similar from location to location—the crescendo of plastic wheels clicking across brightly shined linoleum, beaming fluorescent lights that flicker to life when switched on, mounted fountains of cool hand sanitizer gel. But although oncology units have many similarities, clear differences exist as well.

    November 24, 2017
    Should a Provider Be on Site During Chemotherapy Administration?
    Safety

    Should a Provider Be on Site During Chemotherapy Administration?

    In clinics and oncology floors across the country, IV pumps are infusing, chemotherapy is administered through IV push, and nurses are moving swiftly from one patient to the next. Administering chemotherapy is a complex, in-depth procedure that requires training, education, and a level of experience beyond that of the standard healthcare professional. However, even the best oncology nurses need the support of their team members and the administration to provide the safest possible care environments for their patients.

    September 28, 2017
    chemo resistance with brca mutations
    Cancer research

    Protein May Explain Chemo Resistance in Patients With BRCA2 Mutations

    Researchers have discovered a protein that may lead to a new way to prevent resistance and improve outcomes for patients whose cancers have a BRCA2 mutation. The findings were reported in Molecular Cell.

    September 27, 2017
    Chemotherapy at home
    Chemotherapy

    What Precautions and Recommendations Are Necessary for Patients Receiving Oral Chemotherapy in the Home?

    So far, 2017 has seen an incredible amount of U.S. Food and Drug Administration approvals for new agents and indications. Biotherapy and targeted agents represent many of the newly approved treatment options—a great deal of which are offered in oral form, increasing the opportunity for patients to receive treatment at home.

    September 26, 2017
     Addressing Hypersensitivity Reactions to Chemotherapy
    Safety

    Time Is Short When Addressing Hypersensitivity Reactions to Chemotherapy

    Between administering antineoplastic agents, monitoring patient vitals, and preparing patients for treatment, oncology nurses are required to balance their attention between many intricate tasks. Chief among the division of duties is that oncology nurses closely monitor their patients for hypersensitivity reactions (HSRs) to prescribed agents.

    August 17, 2017
    Scalp Cooling for Chemotherapy-Induced Alopecia
    Treatment side effects

    How Safe and Effective Is Scalp Cooling for Chemotherapy-Induced Alopecia?

    Chemotherapy-induced alopecia has been reported by 77% of patients as the most-feared side effect of cancer treatment. In fact, as many as 10% of women say they would consider refusing chemotherapy or choosing a less effective treatment to avoid losing their hair.

    August 08, 2017
    FDA Update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Liposome-Encapsulated Combination of Daunorubicin-Cytarabine for Patients With AML

    On August 3, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to a liposome-encapsulated combination of daunorubicin and cytarabine (Vyxeos™, Jazz Pharmaceuticals, Inc.) for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC), two types of AML having a poor prognosis.

    August 03, 2017
    hematopoietic stem cell transplant care
    Advanced Practice Nursing (APRN)

    Safely Provide Outpatient Care to Patients Receiving Hematopoietic Stem Cell Transplantations

    High-dose chemotherapy with hematopoietic stem cell support is a well-established treatment for many hematologic malignancies. This treatment can be a difficult journey for patients and families. Historically, patients have been treated in a traditional hospital setting in anticipation of severe side effects, including mucositis, febrile neutropenia, thrombocytopenia, and pulmonary, renal, and hepatic complications. Patients can remain profoundly immunosuppressed for months while recovering from transplant. However, better supportive care in recent years has allowed many centers to move all or a portion of their transplant care into an outpatient setting.

    August 03, 2017
    Chemotherapy administration safeety
    Safety

    Who Is Monitoring Your Infusions for Administration Safety?

    Inquiries received in the ONS clinical inbox often ask about various responsibilities of nurses who hold an ONS chemotherapy provider card and have been deemed competent to administer cancer treatments within their practice setting.

    July 25, 2017
    ONS Congress

    Palonosetron HCL Is a Preferred Treatment for Moderately Emetogenic Chemotherapies

    Chemotherapy-induced nausea and vomiting (CINV) is an adverse event (AE) associated with cancer therapies that healthcare providers often underestimate. CINV can interfere with treatment compliance and adherence, and patients who experienced CINV in the first cycle of chemotherapy are almost four times more likely to experience it during subsequent treatment cycles.

    July 02, 2017
    ASCO Annual Meeting

    Chemotherapy Use Near the End of Life Is More Common in United States

    National guidelines suggest that the use of chemotherapy near end of life (EOL) is aggressive and is associated with poorer patient quality of life. In addition, Medicare payments for outpatient chemotherapy have decreased since around 2005–2006. In a recent study presented at the 2017 ASCO Annual Meeting, researchers evaluated the impact of U.S. payment reform and guidelines on chemotherapy use at EOL, comparing chemotherapy use at EOL in the United States and other countries.

    June 05, 2017
    ASCO Annual Meeting

    Patients Are Equally Satisfied With Phone Calls and In-Person Consultations Before Chemotherapy

    Previous research has indicated that patient satisfaction is linked to time spent with a physician. However, long wait times and organizational issues in an outpatient setting may increase the need for alternative care models. In a study presented at the ASCO Annual Meeting, researchers assessed the use of phone calls instead of a face-to-face consultation prior to chemotherapy (CT) and the effect on patient satisfaction and quality of life.

    June 05, 2017
    • Current page 1
    • Page 2
    • Next page
    • Last page Last »
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2023 Oncology Nursing Society
     
    Back to Top ▲